免疫治疗在卵巢癌中的应用研究进展

Research progress of immunotherapy in ovarian cancer

卵巢癌的临床早期症状不明显,筛查手段有限,就诊时常处于晚期阶段,5年生存率仅30%~45%,严重威胁着女性健康。免疫治疗尤其是免疫检查点抑制剂治疗因其持久的抗肿瘤效应已被批准用于晚期或复发性的多种类型癌症的治疗。目前免疫治疗的一些研究进展为卵巢癌患者的临床管理提供了新的机遇与挑战。

Five-year survival of ovarian cancer is 30%-45% for its non-obvious clinical symptoms, limited screening methods and advanced stage at initial diagnosis, which seriously threatens the health of women. Immunotherapy, especially immune checkpoint blockade, has been approved for treatment for patients with metastatic or recurrent multiple cancers for its durable antitumor effect. Also, the research progress of immunotherapy provides clinical management of ovarian cancer patients with new opportunities and challenges.